ClinicalTrials.gg
RecruitingNCT07518862VARIATIONUpdated Jun 18, 2026

Heart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy

An observational study in Respiratory Failure, Heart Rate Variability (HRV) and High Flow Nasal Cannula, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Respiratory Insufficiency by University Health Network, Toronto — 7 open to participants now, 8 under way, none of them phase 3. Respiratory Insufficiency · University Health Network, Toronto.

Started
2026
the only one that year
Observational
6 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Respiratory Insufficiency by University Health Network, Toronto, this one is the only one that started in 2026, is one of 6 observational ones, and was the 14th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

7 of the 14 studies in Respiratory Insufficiency by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Respiratory Insufficiency by University Health Network, Toronto, or all of them as a file.
02

Study summary

High-flow nasal cannula is a type of non-invasive respiratory support that helps patients breathe more comfortably. Because the flow is high, it can deliver more oxygen to the lungs and make breathing easier by reducing the effort needed to breathe. However, the best strategy to determine the best oxygen flow rate remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited.

Heart rate variability is the natural variation in the time between each heartbeat. Heart rate variability reflects the level of autonomic nervous system activity in response to stress. The autonomic nervous system is the part of the nervous system that automatically controls how heart rate speeds up and slows down. When heart rate variability is higher, it indicates that the system is able to adjust to changes in the body, including stress. However, when heart rate variability is low, it indicates that the system is constrained and in a state of stress.

The VARIATION study is designed to characterize how heart rate variability goal of this observational study is to learn whether heart rate variability can serve as a marker of the appropriateness of high flow nasal cannula flow support during flow titration in patients with respiratory failure. The main question it aims to answer is:

Does heart rate variability change before other conventional respiratory signs when there are changes in respiratory function due to inadequate flow rate?

Participants already on high flow nasal cannula as part of their regular medical care will:

  1. Undergo a stepwise decrease in high flow nasal cannula flow rate.
  2. Be recorded continuously with electrocardiogram and electrical impedance tomography.
Read the detailed description

Previous work has established that high flow nasal cannula can improve outcomes in patients with respiratory failure. However, the optimal approach to titrating HFNC therapy remains uncertain. As a consequence, some patients may be under-supported with HFNC, leading to excessive respiratory muscle effort, while others may be needlessly over-supported, unnecessarily prolonging ICU admission. Prolonged use of HFNC increases costs, but premature decreases in HFNC support may contribute to deteriorations in lung function and delayed recovery, ultimately leading to prolonged hospital stays. Conventional metrics such as respiratory rate are relatively insensitive to early changes in respiratory drive and may therefore fail to detect early respiratory stress in response to reduced flow rates.

One possible approach to monitor the adequacy of HFNC support would be to monitor heart rate variability (HRV). HRV reflects autonomic nervous system function, where healthy individuals exhibit higher HRV, indicating freedom within a biological system to adapt to conditions. HRV is also influenced by respiration, where fluctuations in heart rate at respiratory frequency reflects vagal modulation of cardiac activity.

In patients in the intensive care unit, reduced heart rate variability is a sign of more severe illness. Because the heart and lungs work closely together, and are linked through the autonomic nervous system, changes in respiratory function may affect heart rate variability before more conventional signs of respiratory distress become apparent. Despite these findings, HRV monitoring during HFNC titration remains unexplored.

In this prospective, physiologic crossover study participants will undergo stepwise decreases (from 60 L/min to 20 L/min) in high flow nasal cannula flow rate, while being continuously monitored with electrocardiogram (ECG) and electrical impedance tomography (EIT). The FiO2 will be adjusted to maintain a target SpO2 > 90%. Tidal volume, respiratory rate, FiO2, and SpO2 will be collected and ROX and VOX indices will be collected at each flow rate. Heart rate variability measures will be analyzed from ECG recordings.

If HRV is more sensitive to the physiological effects of HFNC titration compared to conventional respiratory metrics, it could serve as a valuable marker for optimizing flow rate and preventing respiratory deterioration. The results of this project will address a gap in current practice and investigate a physiological marker of respiratory stress that could be used to optimize HFNC weaning strategies.

03

Conditions studied

  • Respiratory Failure
  • Heart Rate Variability (HRV)
  • High Flow Nasal Cannula

Keywords

  • Electrocardiogram (ECG)
  • Electrical Impedance Tomography (EIT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients on high flow nasal cannula for respiratory failure at Toronto General Hospital (UHN)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18
  • Currently receiving High-Flow Nasal Cannula Therapy

Exclusion criteria

Exclusion Criteria:

  • FiO2 ≥ 90%
  • Pacemaker rhythm or presence of atrial fibrillation
  • Post-cardiac surgery patients
  • to electrical impedance tomography (EIT) and/or (ECG) (active implantable medical device, burns, thoracic wounds limiting electrode placement)
  • Non-English-speaking
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in heart rate variability during flow titration

    Time frame: During flow titration, maximum of 1 hour and 45 minutes

Secondary outcomes

  1. Correlation between heart rate variability and respiratory measures during high flow nasal cannula flow titration

    Time frame: During flow titration, maximum of 1 hour and 45 minutes

  2. Agreement between heart rate variability measures derived from pulse oximetry and those derived from ECG

    Time frame: During flow titration, maximum of 1 hour and 45 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 6 months is below that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 9, 2026
StartActual
May 26, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518862
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
May 26, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Rongyu (Cindy) Jin
Contact
rongyu.jin@uhn.ca
4163404800 ext 7613

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion